AI Insight
A large-scale analysis of health records revealed that individuals taking glucosamine, a commonly used joint supplement, showed a 25% increased likelihood of progressing from mild cognitive impairment to dementia. Laboratory studies suggest glucosamine may worsen an abnormal sugar-tagging process observed in Alzheimer's disease brains. Researchers emphasize that clinical trials are necessary to establish whether glucosamine directly causes cognitive harm.
Why it matters
Millions of people worldwide take glucosamine supplements for joint health, often without medical supervision. If confirmed through clinical trials, these findings could have significant public health implications and may require revised guidance on supplement use, particularly for individuals at risk of cognitive decline.
Understand the Science
A large health-record analysis found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest the popular joint supplement may intensify an abnormal sugar-tagging process in the Alzheimer’s brain, although researchers say clinical trials are needed to determine whether it actually causes harm.
Source: Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression